截至发稿，金凯生科市值为44亿元。 每经头条（nbdtoutiao）——爱泼斯坦案文件解密倒计时，美国会"秒过"法案直通特朗普，引爆两党"极 限撕扯" （记者 胡玲） 每经AI快讯，金凯生科（SZ 301509，收盘价：36.5元）11月19日晚间发布公告称，公司股东启鹭（厦 门）股权投资合伙企业（有限合伙）持有公司股份约594万股（占公司总股本比例为4.93%）。启鹭投 资计划通过集中竞价和大宗交易方式减持公司股份不超过约361万股（占公司总股本比例为3%）。其 中，通过集中竞价方式减持股份不超过约120万股，减持比例不超过公司总股本的1%；通过大宗交易方 式减持股份不超过约241万股，减持比例不超过公司总股本的2%。集中竞价的减持期间为自本减持计划 公告之日起十五个交易日后的三个月内；大宗交易的减持期间为自本减持计划公告之日起三个交易日后 的三个月内。 公司股东青岛青松创业投资集团有限公司－青岛松凯创业投资企业（有限合伙）持有公司股份约386万 股（占公司总股本比例为3.21%）。青松投资计划通过集中竞价方式减持公司股份不超过约120万股， 减持比例不超过公司总股本的1%。集中竞价的减持期间为自本减持计划 ...

Core Viewpoint - The shareholders of Jinkai Biotechnology (301509.SZ) plan to reduce their holdings in the company, indicating potential changes in ownership structure and investor sentiment [1] Shareholder Reduction Plans - Qilu Investment plans to reduce its holdings by up to 3.612 million shares, representing no more than 3% of the company's total share capital [1] - Qingsong Investment intends to reduce its holdings by up to 1.204 million shares, accounting for no more than 1% of the company's total share capital [1] - Blue Zone Fund plans to reduce its holdings by up to 2.3391 million shares, which is no more than 1.94% of the company's total share capital [1]

智通财经APP讯，金凯生科(301509.SZ)公告，公司股东启鹭投资计划减持公司股份不超过361.2万股， 减持比例不超过公司总股本的3%。青松投资计划通过集中竞价方式减持公司股份不超过120.4万股，减 持比例不超过公司总股本的1%。蓝区基金计划减持公司股份不超过233.91万股，减持比例不超过公司 总股本的1.94%。 ...

公司股东蓝色经济区产业投资基金（有限合伙）（简称"蓝区基金"）持有公司股份2,339,076股（占公司 总股本比例1.94%）。蓝区基金计划通过集中竞价和大宗交易方式减持公司股份不超过2,339,076股（占 公司总股本比例1.94%）。 格隆汇11月19日丨金凯生科(301509.SZ)公布，股东启鹭（厦门）股权投资合伙企业（有限合伙）（简 称"启鹭投资"）持有公司股份5,936,580股（占公司总股本比例4.93%）。启鹭投资计划通过集中竞价和 大宗交易方式减持公司股份不超过3,612,000股（占公司总股本比例3%）。 公司股东青岛青松创业投资集团有限公司－青岛松凯创业投资企业（有限合伙）（简称"青松投资"）持 有公司股份3,861,074股（占公司总股本比例3.21%）。青松投资计划通过集中竞价方式减持公司股份不 超过1,204,000股，减持比例不超过公司总股本的1%。集中竞价的减持期间为自本减持计划公告之日起 十五个交易日后的三个月内。 ...

证券代码：301509 证券简称：金凯生科 公告编号：2025-039 金凯（辽宁）生命科技股份有限公司 关于公司股东减持股份的预披露公告 股东启鹭（厦门）股权投资合伙企业（有限合伙）、青岛青松创业投资集团 有限公司－青岛松凯创业投资企业（有限合伙）、蓝色经济区产业投资基金（有 限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 金凯（辽宁）生命科技股份有限公司（以下简称"公司"）股东启鹭（厦门）股权 投资合伙企业（有限合伙）（以下简称"启鹭投资"）持有公司股份5,936,580股（占 公司总股本比例4.93%）。启鹭投资计划通过集中竞价和大宗交易方式减持公司股份不 超过3,612,000股（占公司总股本比例3%）。其中，通过集中竞价方式减持股份不超过 1,204,000股，减持比例不超过公司总股本的1%；通过大宗交易方式减持股份不超过 2,408,000股，减持比例不超过公司总股本的2%。集中竞价的减持期间为自本减持计划 公告之日起十五个交易日后的三个月内；大宗交易的减持期间为自本减持计划 ...

Group 1 - The company Jin Kai Sheng Ke stated that as of November 10, 2025, the number of shareholders is expected to be 14,577 [2]

Core Viewpoint - Taihu Xue Company has been awarded the "Most Socially Responsible Listed Company" for its commitment to community development, environmental sustainability, and cultural heritage through innovative practices and industry integration [4][7]. Group 1: Social Responsibility Initiatives - The company has established an ESG committee at the board level to oversee sustainable development strategies and respond to stakeholder expectations [5]. - In response to a natural disaster, Taihu Xue donated over 100,000 yuan worth of bedding supplies to a school in Guizhou province, ensuring children had warm bedding for the winter [5]. Group 2: Industry Integration and Cultural Heritage - Taihu Xue has developed the Taihu Xue Silkworm Culture Park, which combines modern agriculture, silk processing, and cultural tourism, significantly improving the efficiency of silk production [6]. - The company invested 17.91% more in R&D in the first three quarters of 2025, totaling 17.67 million yuan, to enhance silk product offerings and promote Suzhou's cultural heritage through collaborations with local museums [6]. Group 3: Governance and Risk Management - The company has implemented comprehensive risk management procedures to enhance its ability to predict and control risks related to quality, environment, and occupational health [5]. - The governance structure is seen as a foundation for fulfilling social responsibilities, with ongoing improvements to internal control systems [5].

Core Viewpoint - Jinkai Biological (301509) is evaluating the application potential of aromatic amines, which are commonly used organic synthesis intermediates [1] Company Summary - Jinkai Biological has acknowledged the relevance of aromatic amines in organic synthesis and is currently assessing their technological applications [1]

Core Insights - Jinkai Biotechnology, established on June 8, 2009, went public on August 3, 2023, on the Shenzhen Stock Exchange, focusing on small molecule CDMO services in the global life sciences sector [1] - The company provides custom R&D and production services for small molecule drug intermediates and a limited amount of active pharmaceutical ingredients for global innovative drug manufacturers [1] Financial Performance - For Q3 2025, Jinkai Biotechnology reported revenue of 488 million yuan, ranking 21st among 29 peers, with the industry leader WuXi AppTec at 32.857 billion yuan and the average revenue at 2.547 billion yuan [2] - The net profit for the same period was 103 million yuan, placing the company 11th in the industry, with the top performer WuXi AppTec at 12.206 billion yuan and the industry average at 585 million yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 5.22%, down from 6.33% year-on-year, significantly lower than the industry average of 22.79%, indicating strong solvency [3] - The gross profit margin for the same period was 47.43%, up from 39.11% year-on-year, surpassing the industry average of 37.70%, reflecting robust profitability [3] Executive Compensation - The chairman and CEO, Fumin Wang, received a salary of 3.2117 million yuan in 2024, an increase of 225,900 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.48% to 14,100, while the average number of circulating A-shares held per shareholder increased by 1.50% to 4,027.61 [5]

关于开立募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 金凯（辽宁）生命科技股份有限公司（以下简称"公司"或"金凯生科"）于 2025年8月22日召开第二届董事会第八次会议、第二届监事会第八次会议，于2025 年9月22日召开2025年第一次临时股东会，审议通过了《关于使用部分闲置募集资 金（含超募资金）及自有资金进行现金管理的议案》，同意公司在确保不影响募集 资金投资项目建设需要和公司正常经营、并有效控制风险的前提下，公司拟使用不 超过人民币9亿元（含本数）的暂时闲置募集资金（含超募资金）及不超过人民币7 亿元（含本数）的自有资金进行现金管理。上述额度的有效期自公司股东会审议通 过之日起12个月内有效。在上述额度和期限范围内，资金可以循环滚动使用。暂时 闲置募集资金（含超募资金）现金管理到期后将及时归还至募集资金专户。保荐人 出具了无异议的核查意见。具体内容详见公司于2025年8月23日刊登在巨潮资讯网 （www.cninfo.com.cn）上的《关于使用部分闲置募集资金（含超募资金）及自有 资金进行现金管理的公告》（公告 ...